Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dialectic Therapeutics Inc. is currently managing a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio contains 1 pending office action, which represents the current focus of the company's prosecution efforts. This active matter is assigned to 1 distinct examiner, WAX, ROBERT A. This indicates a highly centralized interaction between the company and the patent office, where a single individual is responsible for the initial review of the pending application.
The administrative footprint of this portfolio is limited to 1 distinct art unit. WAX, ROBERT A is also identified as the busiest examiner for the company, currently handling 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this examiner manages the entirety of the company's active workload in the Biotechnology & Pharmaceuticals sector. This structure ensures that all current feedback and requirements originate from a single source.
For practitioners, this data suggests a streamlined prosecution path with no fragmentation across different examiners or art units. The alignment of 1 distinct examiner with 1 distinct art unit for the 1 pending office action allows for a focused strategy. Future filings in the Biotechnology & Pharmaceuticals area may encounter similar administrative assignments, making the current relationship with WAX, ROBERT A a significant factor in the company's patenting process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035923 | Small Molecule Formulation | WAX, ROBERT A | 46d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18035923 | Small Molecule Formulation | WAX, ROBERT A | 1615 | §103 | Non-Final OA | 46d overdue | Pending | May 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDialectic Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert A Wax has the most, with 1 of Dialectic Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
